Zacks Research Equities Analysts Lift Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research increased their Q3 2025 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a research note issued to investors on Wednesday, April 17th. Zacks Research analyst K. Das now expects that the biotechnology company will earn $0.26 per share for the quarter, up from their previous forecast of $0.25. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.92 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.40 EPS, FY2025 earnings at $1.14 EPS and Q1 2026 earnings at $0.39 EPS.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Thursday, February 15th. The biotechnology company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.03. Corcept Therapeutics had a return on equity of 21.98% and a net margin of 21.86%. The business had revenue of $135.41 million during the quarter, compared to the consensus estimate of $129.27 million. During the same period in the prior year, the company posted $0.14 EPS. The firm’s revenue for the quarter was up 31.4% compared to the same quarter last year.

Several other research analysts also recently weighed in on CORT. Truist Financial upped their price target on Corcept Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, HC Wainwright decreased their price objective on Corcept Therapeutics from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, January 2nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $37.30.

Corcept Therapeutics Price Performance

CORT stock opened at $22.66 on Thursday. Corcept Therapeutics has a 1-year low of $20.87 and a 1-year high of $34.28. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of 23.85 and a beta of 0.48. The business has a 50 day simple moving average of $23.93 and a two-hundred day simple moving average of $25.51.

Insider Activity at Corcept Therapeutics

In related news, insider Sean Maduck sold 27,068 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.97, for a total transaction of $702,955.96. Following the sale, the insider now owns 74,455 shares in the company, valued at approximately $1,933,596.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Corcept Therapeutics news, insider Sean Maduck sold 27,068 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.97, for a total value of $702,955.96. Following the sale, the insider now owns 74,455 shares in the company, valued at $1,933,596.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Joseph Douglas Lyon sold 1,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $26.00, for a total value of $26,000.00. Following the completion of the sale, the chief accounting officer now owns 6,774 shares in the company, valued at approximately $176,124. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 83,783 shares of company stock worth $2,118,996. Company insiders own 19.80% of the company’s stock.

Institutional Trading of Corcept Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CORT. JPMorgan Chase & Co. grew its position in shares of Corcept Therapeutics by 2.4% during the 1st quarter. JPMorgan Chase & Co. now owns 216,081 shares of the biotechnology company’s stock worth $4,866,000 after buying an additional 5,036 shares in the last quarter. American Century Companies Inc. grew its position in shares of Corcept Therapeutics by 8.2% during the 1st quarter. American Century Companies Inc. now owns 88,553 shares of the biotechnology company’s stock worth $1,994,000 after buying an additional 6,684 shares in the last quarter. Citigroup Inc. grew its position in shares of Corcept Therapeutics by 15.0% during the 1st quarter. Citigroup Inc. now owns 103,241 shares of the biotechnology company’s stock worth $2,325,000 after buying an additional 13,488 shares in the last quarter. Natixis Advisors L.P. grew its position in shares of Corcept Therapeutics by 56.7% during the 1st quarter. Natixis Advisors L.P. now owns 18,581 shares of the biotechnology company’s stock worth $418,000 after buying an additional 6,726 shares in the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of Corcept Therapeutics by 3.3% during the 1st quarter. Acadian Asset Management LLC now owns 31,845 shares of the biotechnology company’s stock worth $716,000 after buying an additional 1,032 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.